For more recent news features related to this topic, please click on a link to the left.
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
Business Wire India
CHMP Adopts Negative Opinion on Appeal on European Application for natalizumab for the Treatment of Crohn's Disease
Business Wire India
Elan and Biogen Idec Announce that FDA will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease
Business Wire India
Biogen Idec and Elan Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis
Business Wire India
New TYSABRI(R) Data to Be Presented at the European Committee for Treatment and Research in Multiple Sclerosis
Business Wire India
Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline Presentations at the European Committee for Treatment and Research of Multiple Sclerosis
Business Wire India
TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology
Business Wire India
Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease
Business Wire India
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
Business Wire India
This page represent a snapshot of events / happenings related on select news topics. The links on this page might not completely depict the series of events related to the event and in some cases information on the page might not be comprehensive.